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The innate immune sensor Toll-like receptor 2 controls 
the senescence-associated secretory phenotype
Priya Hari1, Fraser R. Millar1, Nuria Tarrats1, Jodie Birch2, Andrea Quintanilla1, Curtis J. Rink3,4, 
Irene Fernández-Duran1, Morwenna Muir1, Andrew J. Finch1, Valerie G. Brunton1,  
João F. Passos2,5, Jennifer P. Morton3,4, Luke Boulter6, Juan Carlos Acosta1*
Cellular senescence is a stress response program characterized by a robust cell cycle arrest and the induction of 
a proinflammatory senescence-associated secretory phenotype (SASP) that is triggered through an unknown 
mechanism. Here, we show that, during oncogene-induced senescence (OIS), the Toll-like receptor 2 (TLR2) and 
its partner TLR10 are key mediators of senescence in vitro and in murine models. TLR2 promotes cell cycle arrest 
by regulating the tumor suppressors p53-p21CIP1, p16INK4a, and p15INK4b and regulates the SASP through the induc-
tion of the acute-phase serum amyloids A1 and A2 (A-SAAs) that, in turn, function as the damage-associated mo-
lecular patterns (DAMPs) signaling through TLR2 in OIS. Last, we found evidence that the cGAS-STING cytosolic 
DNA sensing pathway primes TLR2 and A-SAAs expression in OIS. In summary, we report that innate immune sens-
ing of senescence-associated DAMPs by TLR2 controls the SASP and reinforces the cell cycle arrest program in OIS.
INTRODUCTION
Cellular senescence is a cell cycle arrest program induced by various 
stresses that renders cells insensitive to mitogenic signals and im-
pairs the proliferation and expansion of damaged cells (1). Activa-
tion of oncogenes such as RAS in somatic cells induces a senescence 
program termed oncogene-induced senescence (OIS) (2). OIS is a 
cell-intrinsic tumor suppressor mechanism that impairs tumor pro-
gression (2–7). Senescence is also characterized by the activation of 
the senescence-associated secretory phenotype (SASP). The SASP is a 
cocktail of proinflammatory cytokines, chemokines, growth factors, 
and matrix-remodeling proteins with diverse functions and roles 
(8–10). Through the SASP, senescent cells elicit multiple paracrine 
effects to promote the normal processes associated with inflamma-
tion, wound healing, tissue remodeling, and cell plasticity (11–14) 
or it can disrupt tissue homeostasis, promoting aging and other 
pathophysiological conditions such as fibrosis and cancer (12). The 
SASP reinforces the cell cycle arrest by activating p53 and the cell 
cycle inhibitors p21CIP1 and p15INK4b (8, 10, 15). The SASP also pro-
motes paracrine senescence (15) and stimulates immune surveillance 
that results in clearance of the senescent cells (16–18), which collect-
ively contribute to the tumor suppressor program elicited by 
OIS. Therefore, the immune system can regulate senescence and 
determine senescent cell fate (19–21).
The activation of the SASP is primarily regulated by the tran-
scription factors nuclear factor B (NF-B) and CCAAT/enhancer- 
binding protein  (C/EBP) (8, 10, 22). SASP activation responds to 
a hierarchical model where interleukin-1 (IL-1) and IL-1 are the 
apical cytokines signaling through IL-1 receptor (IL-1R), triggering 
a cascade of additional amplifying feedback loops by other cytokines 
and chemokines of the SASP. As a consequence, NF-B and C/EBP 
activation are sustained, and the expression of the SASP is main-
tained. Interfering with these feedback loops, such as the one set up 
by IL-1, IL-6, or IL-8, collapses the network, impairing the induction 
of the SASP and the activation of the cell cycle arrest (8, 10, 15, 23).
We have previously shown that the inflammasome regulates the 
activation of the SASP (15). The inflammasome is a multiprotein 
platform that induces the proteolytic activity of the inflammatory 
cysteine-aspartic protease Caspase-1. It is a key regulatory compo-
nent of the innate immune response and the first line of defense 
against pathogens and damage (24). Activation of the inflammasome 
leads to cleavage and activation of the proinflammatory cytokine 
IL-1. Inflammasomes are controlled by a family of receptors called 
pattern recognition receptors (PRRs). PRRs are receptors of the in-
nate immune system that are activated by interaction with pathogen- 
associated molecular patterns (PAMPs) or with damage-associated 
molecular patterns (DAMPs) that are generated endogenously in 
cells under certain conditions of stress and damage (25). There are 
three major PRR families: Toll-like receptors (TLRs), RIG-I–like 
receptors, and NOD-like receptors (25). Upon activation, PRRs in-
duce distinct signal transduction pathways that activate an immune 
transcriptional program mostly regulated by NF-B and interferon 
regulatory factors (IRFs).
Although the steady-state signaling of the SASP is relatively well 
understood, the molecular mechanism(s) that initiates the SASP in 
OIS and how the inflammasome is primed during OIS remain ill 
defined. Here, we describe the mechanism that underlies the priming 
of the inflammasome in OIS by PRRs, identifying the senescence- 
associated DAMP that initiates the SASP and reinforces OIS.
RESULTS
The innate immune receptor TLR2 is induced during 
cellular senescence
To study OIS, we used the well-characterized IMR90 human diploid 
fibroblast cell line transduced with an Estrogen Receptor:H-RASG12V 
fusion protein (henceforth referred to as ER:RAS). ER:RAS oncogenic 
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activity is induced after addition of 4-hydroxytamoxifen (4OHT) 
to the cultures, resulting in a time-controlled OIS response as previ-
ously described (15) (Fig. 1A). Gene set enrichment analysis (GSEA) 
of the transcriptome of IMR90 ER:RAS senescent cells showed an 
enrichment for “innate immunity,” “PRR,” and “TLR” terms (fig. S1A). 
Therefore, we decided to explore the role of TLRs in OIS. Analysis 
of the gene expression of all 10 human TLR genes showed a marked 
induction of TLR2 expression in OIS (Fig. 1B and fig. S1, B and C). 
The induction of TLR2 mRNA correlated with an increase in TLR2 
protein (Fig. 1C), which corresponded with the cell cycle arrest 
during OIS (Fig. 1C). The induction of TLR2 was also observed 
after additional OIS by retroviral transduction of oncogenic H-RasG12V, 
by the activation of senescence with a DNA damage-inducing agent 
(etoposide), and by conditioned medium from OIS cells (paracrine 
senescence) (fig. S1, B to E) (15). However, the induction of se-
nescence with nongenotoxic agents such as the cyclin-dependent 
kinase 4 (CDK4) inhibitor palbociclib or the mouse double minute 2 
homolog (MDM2) inhibitor Nutlin 3a failed to induce TLR2 and the 
SASP (fig. S1, B and C), suggesting that the activation of TLR2 ex-
pression is associated to genotoxic stress.
In vivo, we analyzed tlr2 expression in four well-characterized 
mouse models of senescence. We first examined the expression of 
tlr2 in a murine model of OIS, in which conditional expression of 
KrasG12D by Pdx-CRE (KC mouse) induces pancreatic intraepithelial 
neoplasia (PanIN) (26). A marked induction of Tlr2 was observed 
in ductal pancreatic cells in PanINs with low Ki67 indexes, indicating 
that Tlr2 is expressed in early senescent PanINs (fig. S2A). We then 
investigated an additional model where OIS is induced in murine 
hepatocytes via hydrodynamic delivery of a mutant NrasG12V encoding 
transposon along with a sleeping beauty transposase–expressing 
plasmid (16). A plasmid encoding an NrasG12V effector loop mutant, 
incapable of downstream Nras signaling (NrasG12V/D38A), was used 
as a negative control. Six days after NrasG12V transduction, tlr2 
mRNA expression was significantly increased in comparison to 
controls (Fig. 1D), which correlated with the expected induction of 
mRNA expression of the senescence markers dcr2 and arf and the 
SASP factor IL-1 (fig. S2B). To investigate whether tlr2 induction 
in this model derives from Nras-expressing hepatocytes or recruited 
immune cells, we performed immunohistochemistry (IHC) for Nras 
and Tlr2 protein expressions in consecutive liver sections. Analysis 
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Fig. 1. TLR2 expression is induced during OIS. (A) Schematic showing IMR90 ER:RAS cells treated with 4OHT undergo OIS. IMR90 ER:STOP cells serve as a control and 
retain proliferative capacity with 4OHT. (B) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of TLR family member expression in IMR90 
ER:RAS and ER:STOP cells treated with 4OHT for 5 and 8 days. (C) Western blot of TLR2 expression in IMR90 ER:RAS and ER:STOP (ER:S) cells with up to 10 days of 4OHT 
treatment (top). The 5-bromo-2′-deoxyuridine (BrdU) incorporation in IMR90 ER:RAS cells treated with 4OHT for up to 8 days, as indicated. (D) RNA was extracted from 
snap-frozen liver samples from wild-type (WT) mice 6 days following hydrodynamic delivery of NrasG12V/D38A (n = 5) and NrasG12V (n = 4) transposons. tlr2 mRNA expression 
was measured using qRT-PCR. Scatter plots represents value per animal, with the horizontal line representing group means ± SEM. Statistical significance was calculated 
using Students two-tailed t test. **P < 0.01. (E) Immunohistochemical staining for Nras and Tlr2 in consecutive liver sections from corresponding mice in (D) showing that 
oncogenic NrasG12V expressing, but not NrasG12V/D38A expressing, hepatocytes express Tlr2. Scale bars, 50 m.
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of these sections revealed that the expression of Tlr2 was induced in 
hepatocytes of mice transduced with active Nras and was not present 
in the inactive control (Fig. 1E). Moreover, superposition of consec-
utive sections stained for Nras and Tlr2 showed an overlap between 
both signals, suggesting that the hepatocytes expressing active 
NrasG12V are indeed the cells overexpressing Tlr2 (Fig. 1E and fig. 
S2C). We then investigated the expression of tlr2 in a model of 
inflammatory-mediated senescence, where knockout of nfkb1 
(nfkb1−/−) in mice leads to constitutive activation of NF-B (27). An 
increased number of airway epithelial cells expressing Tlr2 were 
detected, which correlated with p21Cip1 expression in the lung airways 
(fig. S2D). Last, we observed an increase in the number of cells 
positively expressing Tlr2 in alveolar cells of the lung in aged mice 
(fig. S2E). These results indicate that TLR2 is induced in cellular 
senescence.
TLR2 controls the activation of the SASP in OIS
We previously identified that activation of IL-1R signaling by the 
inflammasome was essential for the induction of the SASP (15). 
However, before inflammasome activation, the expression of IL-1 
should be primed (28, 29). TLR2 forms functional heterodimers 
with three other TLRs: TLR1, TLR6, and TLR10 (30–32). To evaluate 
the activity of all four members of the TLR2 network in IL-1 priming, 
we knocked down their expression during OIS using four pooled 
small interfering RNAs (siRNAs) (fig. S3A). While knockdown of 
TLR1 and TLR6 marginally decreased the expression of IL-1, 
TLR2 and TLR10 knockdown strongly decreased its induction 
(Fig. 2, A to C, and fig. S3B), suggesting a predominant role for 
these receptors in priming the inflammasome in OIS. To rule out 
off-target effects from the siRNAs, we tested all four individual siRNAs 
from the TLR2 and TLR10 pool. Each siRNA produced efficient 
TLR2 knockdown in IMR90 ER:RAS cells (fig. S3C) and decreased the 
expression of IL-1 in OIS (fig. S3D). Similarly, two single siRNAs 
from the pooled siRNA also efficiently reduced the expression of 
TLR10 and impaired IL-1 transcriptional activation (fig. S3, C and E). 
TLR2 and TLR10 knockdown resulted in reduced production of 
mature active IL-1 (Fig. 2B) and a decrease in the accumulation of 
mature IL-1 in conditioned media of IMR90 ER:RAS cells (fig. S3B), 
indicating a crucial role for the TLR2 network for the inflammasome 
function in senescence. Inflammasome activation is a key step in 
the induction of the SASP during OIS (15). Therefore, we studied 
the effect of TLR2 signaling in SASP induction. Targeting TLR2 and 
TLR10 with siRNA impaired the induction of mRNA expression of 
the SASP components IL-1, IL-6, IL-8, CCL20, matrix metallopro-
teinase 1 (MMP1), MMP3, and inhibin beta A (INHBA) (Fig. 2C) 
and blocked the induction of IL-8 and IL-6 proteins (Fig. 2B and fig. 
S3F). Moreover, inhibition of TLR2 with oxidized-1-palmitoyl-
2-arachidonyl- sn-glycero-3-phosphorylcholine (OxPAPC) signifi-
cantly reduced IL-1 and IL-1 mRNA induction in OIS (fig. S3G). 
Last, knockdown of TLR2 and TLR10 in IMR90 cells impaired the 
induction of IL-1, IL-6, and IL-8 when exposed to conditioned media 
from senescent IMR90 ER:RAS cells, indicating a contribution of TLR2 
in the propagation of the SASP during paracrine senescence (fig. S3H).
We then performed a transcriptomic analysis of more than 
20,000 genes of IMR90 ER:RAS cells transfected with siRNA targeting 
TLR2 and TLR10 (fig. S3I). We found that TLR2 knockdown 
significantly regulated more than 1000 genes, while TLR10 knockdown 
regulated up to 2500 genes (fig. S3I and data file S1). From the total 
number of genes positively regulated by TLR2 and TLR10 in OIS, 
267 were common targets, indicating a high degree of overlap 
between genes positively regulated by TLR2 and TLR10 (Fig. 2D and 
data file S2). The vast majority of genes regulated by TLR10 in OIS 
(956) were also not controlled by TLR2 in these experimental 
conditions (Fig. 2D and data file S3). Gene ontology analysis of 
these genes indicated a significant enrichment in “nucleotide binding 
proteins”–related terms (fig. S3J). In contrast, gene ontology analysis 
of the genes commonly regulated by TLR2 and TLR10 in OIS showed 
enrichment for terms related to “inflammatory response,” “chemotaxis,” 
“chemokine activity,” and “extracellular space” (Fig. 2E). Moreover, 
the analysis revealed that TLR2 and TLR10 regulated the expression 
of most of the proinflammatory SASP, most notably chemokines, 
cytokines, and metalloproteases (Fig. 2F). TLR2 signals through 
NF-B and p38 mitogen-activated protein kinase (MAPK) (33), 
which are key SASP regulators. A significant enrichment in genes 
regulated by NF-B in OIS (22) was observed in the transcriptome 
of control cells compared to TLR2-depleted cells (Fig. 2G), indicating 
an essential role for TLR2 signaling in NF-B activation in senes-
cence. To confirm this, we targeted TLR2 and TLR10 with siRNA in 
4OHT-treated IMR90 ER:RAS cells and showed a decrease in NF-B 
pathway activation [reduced inhibitor of nuclear factor B kinase 
/ (IKK/) and p65 phosphorylation] (Fig. 2, H and I). We also 
observed a marked decrease in p38 MAPK phosphorylation in 
TLR2- and TLR10-depleted cells in OIS (Fig. 2H). These results 
show that TLR2 signaling is a significant contributor to the activation 
of the SASP by controlling NF-B and p38 MAPK signal transduction 
pathways. Together, these data indicate that TLR2 signaling is 
necessary for the induction of the SASP.
TLR2 reinforces the cell cycle arrest program in OIS
Activation of the SASP reinforces the cell cycle arrest program in 
senescence (8, 10). Moreover, p38 MAPK is a significant regulator 
of OIS, controlling the activation of p53 and p16INK4a tumor sup-
pressor genes (34). Inhibition of p38 MAPK, but not of NF-B, 
with chemical compounds bypassed the proliferative arrest and 
impaired p21CIP1 activation in IMR90 ER:RAS cells, showing a 
role for p38 MAPK in the reinforcement of the cell cycle arrest in 
OIS (fig. S4, A and B). Given the integral role TLR2 plays in the 
regulation of the SASP and p38 MAPK, we explored whether 
TLR2 also controls the cell cycle arrest in OIS. Overexpression of 
TLR2 induced cell cycle arrest and an increase in the number of 
senescence-associated -galactosidase (SA--Gal)–positive cells 
(Fig. 3, A and B). Analysis of proliferation after ER:RAS activation 
showed that targeting TLR2 and TLR10 with siRNA strongly 
reduced the cell cycle arrest associated with OIS (Fig. 3C) and 
increased the long-term growth of ER:RAS cells (Fig. 3D and fig. S4, 
C and D). This effect correlated with a decrease in the number of 
cells positive for SA--Gal activity 10 days after ER:RAS activation 
(Fig. 3E). The control of proliferation by TLRs was specific for 
TLR2 and TLR10, as knockdown of the other eight members of 
the human TLR family did not show bypass of the cell cycle arrest 
program (fig. S4E). Suppression of TLR2 and TLR10 resulted in a 
decrease in p21CIP1, p16INK4a, and p15INK4b mRNA expression 
(Fig. 3F) and a reduction of p53 protein levels (Fig. 3G). In addition, 
TLR10 knockdown induced escape of cell cycle arrest in cells 
subjected to conditioned media from OIS cells, suggesting a role 
in cell cycle arrest during paracrine senescence (fig. S4F). Together, 
these results indicate that TLR2 contributes to the cell cycle arrest 
program induced during OIS.
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Fig. 2. TLR2 and TLR10 regulate the SASP in OIS. (A) Immunofluorescence staining and high-content analysis for IL-1 expression in IMR90 ER:RAS cells treated with 4OHT 
for 8 days and repeatedly transfected with pooled siRNA targeting TLR1, TLR2, TLR6, and TLR10. Nontarget (NT)-pooled siRNA was used as control. Representative images are 
shown. Scale bars, 250 m. DAPI, 4′,6-diamidino-2-phenylindole. (B) Western blot analysis against indicated antibodies in IMR90 ER:RAS cells treated with 4OHT for 8 days and 
repeatedly transfected with pooled and individual siRNA targeting TLR2 and TLR10. T2-P, siRNA TLR2 pool; T2-4, individual TLR2 siRNA; T10-P, siRNA TLR10 pool; T10-2, 
individual TLR10 siRNA. Nontarget pooled siRNA was used as control. Western blot against -actin is shown as a loading control. (C) SASP factor regulation by qRT-PCR in 
ER:RAS cells treated with 4OHT for 8 days and repeatedly transfected with pooled siRNA targeting TLR2 and TLR10. Results are expressed as means ± SEM of three independent 
experiments. (D) Venn diagram showing the number of genes that are significantly induced by TLR2 and TLR10 during OIS in the transcriptome analysis (AmpliSeq) in 
IMR90 ER:RAS cells treated with 4OHT and transfected with pooled siRNA targeting TLR2 and TLR10 for 8 days (GSE127116). The intersection represents the number of genes 
regulated by both TLR2 and TLR10. This signature of 267 genes will be used for GSEA in additional senescence transcriptomes in Fig. 4 and figs. S4 and S7. (E) Top regulated 
terms identified through of coregulated genes in (H) using DAVID gene ontology analysis. Chart bars represent Benjamin- adjusted P value of term enrichment. (F) Heat map 
of SASP factor expression obtained from the transcriptome analysis (AmpliSeq) in IMR90 ER:RAS cells following siRNA knockdown of TLR2 and TLR10 for 8 days of 4OHT treat-
ment. (G) GSEA enrichment plot of RELA signature in TLR2 siRNA-transfected IMR90 ER:RAS 4OHT-induced cells. (H) IMR90 ER:RAS cells were transfected with indicated siRNA 
for 8 days with 4OHT. Western blot for phosphorylation and total levels of IKK/ and p38 mitogen-activated protein kinase (MAPK) was performed. (I) IMR90 ER:RAS cells were 
treated with 4OHT and repeatedly transfected with indicated pooled siRNA and nontarget siRNA as control for 5 days. Western blots were conducted for phosphorylation 
of p65 and total p65 protein levels. All statistical significance was calculated using one-way analysis of variance (ANOVA). ***P < 0.001, **P < 0.01, and *P < 0.05. ns, not significant.
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TLR2 controls the expression of acute-phase serum amyloids 
A1 and A2, which are components of the SASP
GSEA of the transcriptome of TLR2- and TLR10-targeted cells 
revealed “acute-phase response” and “positive regulation of acute 
inflammatory response” as the top gene ontology terms (highest 
enrichment score and significance) for both conditions (fig. S5A). 
The acute-phase response is a clinical indication of an inflammatory 
event such as infection, trauma, or neoplasia and is characterized by 
the production and secretion of acute-phase proteins, including 
C-reactive protein and acute-phase serum amyloids by the liver 
(35). The two genes most strongly down-regulated by TLR2 and 
TLR10 knockdown were acute-phase serum amyloids A1 and A2 
(SAA1 and SAA2; A-SAAs hereinafter) (Fig. 4A). Other genes 
annotated as acute-phase response, such as IL-1, IL-1, IL-6, 
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SERPINA3, ASS1, and PTGS2, also showed strong regulation by TLR2 
and TLR10 in OIS (Fig. 4A). Further mRNA analysis by quantita-
tive reverse transcription polymerase chain reaction (qRT-PCR) of 
SAA1, SAA2, SERPINA3, PTGS2, STAT3, and IL-6R expression con-
firmed these results (Fig. 4B), indicating that the expression of A-SAAs 
is highly induced during OIS and is dependent on TLR2 and TLR10. 
A time-course analysis of OIS revealed that A-SAA expression is 
induced 5 days after the activation of oncogenic RAS with 4OHT, 
which overlaps with TLR2 induction (Figs. 1C and 4C, and fig. 
S5B). Treatment of IMR90 cells with Pam2CSK4 (a synthetic ago-
nist for TLR2) induced A-SAA expression, which was increased 
by one order of magnitude by ectopic overexpression of TLR2 (fig. 
S5C), suggesting a role for TLR2 sensing in the induction of A-SAAs 
in OIS. Western blot of the conditioned medium from IMR90 ER:RAS 
cells showed an accumulation of A-SAAs, which was reduced 
following siRNA knockdown of SAA1 and SAA2 (Fig. 4D and fig. S5D), 
suggesting that A-SAAs are components of the SASP. Similar to 
TLR2, A-SAA induction was associated to genotoxic stress. While 
induction of senescence with a genotoxic agent such as etoposide 
induced the expression of A-SAAs, direct induction of p53 activity 
with Nutlin 3a or by CDK4 inhibition with palbociclib failed to 
activate A-SAA expression (fig. S5E). We then studied the induction 
of A-SAAs in senescence in vivo. mRNA expression of saa2 was 
induced in the lung of nfkb1 knockout mice in parallel with the 
senescence markers cdkn1a (p21) and cdkn2a (p16) (fig. S5F). 
Moreover, increased expression of Saa1 was detected in early, 
low-proliferative PanINs in the KC mouse (fig. S5G). In summary, 
these results show that A-SAAs are components of the SASP 
regulated by TLR2.
A-SAAs are potent senescence-associated DAMPs that 
control the SASP through TLR2 signaling
Previous reports have shown that A-SAAs have cytokine-like activity 
by interacting with TLR2 (36). Thus, we decided to explore the role 
of A-SAAs regulating the SASP in OIS. Recombinant A-SAA 
(rA-SAA) induced IL-1 mRNA expression with a similar effect to 
that achieved with an equimolar dose of the synthetic TLR2 agonist 
Pam2CSK4 (fig. S6A). Also, TLR2 overexpression in IMR90 cells 
enhanced rA-SAA–dependent induction of the SASP (fig. S6, B and C). 
Interference of TLR2 function with neutralizing antibodies (fig. S6D) 
or with siRNA against TLR2 and TLR10 (Fig. 4E and fig. S6E) also 
inhibited the rA-SAA–mediated induction of SASP components 
and SAA2. These results suggest that A-SAAs directly activate 
TLR2, resulting in priming of the inflammasome and SASP induction. 
To further confirm this, we decided to target the expression of A-SAAs 
during OIS with siRNA, showing that the induction of IL-1 and 
the SASP (Fig. 4, F and G) and the accumulation of mature IL-1 
and IL-8 in conditioned media (Fig. 4D) were impaired when 
A-SAA was targeted. Moreover, treatment of IMR90 ER:RAS cells 
transfected with SAA2 siRNAs with the TLR2 agonist Pam2CSK4 
rescued the induction of the SASP (Fig. 4H), confirming that TLR2 
requires the presence of A-SAAs or additional exogenous DAMPs 
for the activation of the SASP. Together, these data indicate that 
A-SAAs are the DAMPs that signal through TLR2 to prime the 
inflammasome and regulate the SASP in OIS.
To assess the relative importance of TLR2- and A-SAA–mediated 
SASP regulation, we compared the effect of TLR2, TLR10, and SAA2 
with other previously described regulators of the SASP, including the 
DNA damage response (DDR)  pathway [ataxia-telangiectasia mu-
tated (ATM)], the cyclic GMP-AMP synthase - stimulator of inter-
feron genes (cGAS-STING) cytosolic DNA sensing pathway, the 
master SASP regulator IL-1 (IL-1R), the mechanistic target of rapa-
mycin (mTOR) pathway, and the essential SASP transcription factors 
NF-B (RELA) and C/EBP (37). Knockdown of the A-SAA–TLR2 
pathway had a similarly negative effect on IL-1 induction to that 
following knockdown of the other known SASP regulators (fig. S6, F 
and G). In addition, knocking down the other A-SAA Toll-like re-
ceptor TLR4 did not decrease IL-1, suggesting a specific role for 
A-SAA–TLR2 signaling in OIS (fig. S6G).
Last, we wanted to assess the existence of this regulatory pathway 
in additional cell types and senescence triggers. We first explored 
the expression of TLR2, SAA1, and SAA2 in available transcriptomic 
datasets of senescence (Fig. 4H). This analysis revealed that the 
A-SAA–TLR2 pathway was induced in senescence activated by 
acute stresses, such as therapy-induced senescence in lymphoma 
cells (38), BRAFV600E-induced senescence in human melanocytes 
(39), stasis in primary human mammary epithelial cells (40), and 
DDR-induced senescence in human dermal fibroblasts (BJ) (41), while 
it was not induced in replicative senescence (41) and programmed 
developmental senescence in the murine mesonephros (Fig. 4H) 
(42). Notably, the gene set composed of the 267 genes coregulated 
by TLR2 and TLR10 in OIS (Fig. 2D) was significantly enriched 
(P < 0.01) only in those transcriptomes with activation of A-SAA–
TLR2 expression (Fig. 4I), while this correlation was not found with the 
transcriptome of replicative and developmental senescence (fig. S5H), 
suggesting a role for the A-SAA and TLR2 pair in senescence induced 
by several acute stresses in distinct cell types. Together, these results 
indicate that A-SAAs and TLR2 establish a master innate immune 
pathway with a key role in the control of the transcriptome in senescence.
The cGAS-STING cytosolic DNA sensing pathway controls 
the induction of TLR2 and A-SAAs in OIS
Experiments targeting RELA and ATM revealed that the activation 
of TLR2 and A-SAAs is dependent on NF-B and the DDR in OIS 
(Fig. 5A). Recently, it has been shown that, in senescence, NF-B is 
activated by the cGAS-STING cytosolic DNA sensing pathway by 
the accumulation of cytoplasmic chromatin fragments released 
from the damaged nucleus in response to genotoxic stress (43). 
Thus, we speculated that this pathway could be responsible for the 
induction of TLR2 and A-SAAs in OIS. Inactivation of cGAS and 
STING with siRNA in OIS strongly impaired the transcriptional 
activation of TLR2, SAA1, and SAA2 mRNA expression (Fig. 5B), 
indicating a role for the DNA sensing pathway in the regulation of 
TLR2 and A-SAAs. Moreover, direct activation of cGAS-STING by 
transfecting double-stranded DNA (dsDNA) into IMR90 cells 
induced the formation of STING homodimers, which is a hallmark 
of its activation, and induced TLR2 expression, which was reduced 
by STING knockdown (Fig. 5, C and D). STING signals through the 
NF-B and the interferon response pathways to transcriptionally 
activate its target genes. To elucidate how the cGAS-STING pathway 
induces the expression of TLR2 and A-SAAs, we knocked down 
RELA and IRF3 in cells transfected with dsDNA, showing that the 
inactivation of the NF-B pathway with siRNA against RELA, 
but not IRF3, impaired TLR2 and A-SAA induction in IMR90 
cells (Fig. 5C and fig. S6, I and J). Moreover, in contrast to RELA 
knockdown (Fig. 5A), IRF3 targeting did not impair TLR2 in-
duction in OIS (fig. S6K), suggesting a specific role for the NF-B 
pathway downstream of STING in TLR2 induction in OIS. Last, 
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knockdown of TLR2 and TLR10 did not reduce the formation of 
STING homodimers in OIS (Fig. 5D), suggesting that TLR2 signaling 
is the downstream of the cGAS-STING pathway. Together, these 
results indicate that A-SAAs and TLR2 are downstream of the 
cGAS-STING cytosolic DNA sensing pathway in OIS.
TLR2 regulates the SASP and OIS in vivo
The strong enrichment of the TLR2/TLR10 OIS-dependent gene set in 
the publically available transcriptome of KrasG12D-driven PanINs in 
KC mice (44) suggested a role for TLR2 in this in vivo model (fig. S7A). 
Therefore, we decided to test the effect of knocking out tlr2 (tlr2−/−) 
on SASP activation in KC mice. We observed a reduction in IL-1 
staining in PanIN epithelial cells of tlr2−/− mice compared to wild-
type (WT) mice (Fig. 6A), indicating a causal role for TLR2 in the 
activation of the SASP in PanIN. We also assessed the effect on 
SASP expression after hydrodynamic delivery of NrasG12V trans-
posons into hepatocytes of tlr2−/− mice (Fig. 6, B and C). The transduc-
tion of oncogenic NrasG12V, but not of the inactive NrasG12V/D38A, 
induced IL-1, IL-1, and IL-6 mRNA expression (Fig. 6B) and the 
accumulation of IL-1– and Tlr2-positive hepatocytes (Fig. 6C) in 
WT mice. In contrast, NrasG12V failed to induce IL-1– and Tlr2- 
positive hepatocytes and IL-1 mRNA expression in the liver of 
tlr2−/− mice (Fig. 6, B and C). Moreover, the induction of other 
SASP components, IL-1 and IL-6, was also impaired in tlr2−/− 
mice (Fig. 6B). NrasG12V-induced senescence, measured by the 
increase in p21 or biotinylated Sudan Black B (Biotin-SBB)–positive 
hepatocytes (Fig. 6C) and in SA--Gal activity in the whole liver 
(fig. S7B), was impaired in tlr2−/− mice. In summary, these results 
indicate that tlr2 is necessary for the induction of the SASP and the 
activation of OIS in vivo.
DISCUSSION
We describe here an essential innate immune signaling pathway 
in OIS established between TLR2 and A-SAAs that initiates the SASP 
and reinforce cellular senescence in vitro and in vivo (fig. S7C). We also 
identify new important SASP components, A-SAAs, which are the 
senescence-associated DAMPs sensed by TLR2 after oncogenic stress. 
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(C) Representative IHC staining for Nras, Tlr2, IL-1, p21, and Biotin-SBB in corresponding liver sections from mice in (B). Scale bars, 50 m.
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Therefore, we are reporting that innate immune sensing is critical 
in senescence.
We propose that cellular senescence shares mechanistic features 
with the activation of innate immune cells and could be considered 
a program of the innate immune response by which somatic cells switch 
their regular role to acquire an immune function under certain 
conditions of stress and danger, for instance, upon oncogene activation. 
In OIS, super-enhancer elements regulated by Bromodomain- 
containing protein 4 (BRD4) adjacent to the SASP have been 
shown to regulate the immune surveillance of senescent cells (45). 
In the same study, it was demonstrated that TLR pathways in general, 
and TLR2 in particular, were associated with activation of typical 
enhancers during OIS, suggesting that enhancer remodeling might 
shape the switch that activates this immune sensing program during 
senescence. In addition, cytosolic DNA sensing by the innate im-
mune sensor cGAS has also been identified as an essential step in 
the activation of the SASP (43, 46). In our study, we have shown 
that the induction of TLR2 and A-SAAs depends on the activa-
tion of cGAS and STING in senescence, and they appear to function 
downstream of STING to regulate the SASP and NF-B (fig. S7C). 
Future research will be necessary to understand further the cross-
talk between both pathways in senescence. For example, Dou et al. 
proposed that p38 MAPK signaling impairs the activation of the 
interferon response arm of the cGAS-STING pathway, prioritizing 
the NF-B response (43). In agreement, our data suggests that TLR2 
and A-SAA expression is regulated through the NF-B, but not 
the IRF3, pathway downstream of cGAS-STING. We observed 
that TLR2 is essential for both the steady-state activation of p38 
MAPK and NF-B during OIS. Therefore, it is tempting to specu-
late that TLR2 may interact with the cGAS-STING pathway in 
senescence by actively impairing the activation of interferon response 
genes. As a result of these net interactions between innate immune 
receptors, TLR2 signaling is critical for the SASP and the cell cycle 
arrest and coincides with the role of both p38 MAPK and NF-B 
signal transduction pathways in OIS (8, 10, 22, 34).
In our experiments, we observed that TLR10 regulates a larger 
number of genes than TLR2. In contrast to the TLR2/10 coregulated 
genes, TLR10-specific genes were not directly related to inflamma-
tion. TLR10 is a largely under-characterized gene with undefined 
function, and in mice, it is a pseudogene inactivated by serial retro-
transposition (32). Our study suggests a potential specific role for 
TLR10 in cellular senescence in human cells, with some possible 
TLR2-independent functions. However, further research will be 
necessary to clarify whether this subject is real or is the result of the 
higher efficiency of the siRNA reagent or the relative abundance 
between TLR2 and TLR10.
Besides revealing a role for TLR2 in SASP induction and cell 
cycle regulation, we identified the DAMP that activates TLR2 in 
OIS. Acute-phase proteins SAA1 and SAA2 act to prime the 
TLR2-mediated inflammasome, and in turn, their full induction 
depends on TLR2 function. Hence, they establish a foundational 
feedback loop that controls the SASP (fig. S7C). A-SAAs are systemi-
cally produced in the liver and released into the bloodstream during 
an acute inflammatory response (35). Our identification of these 
molecules as mediators of senescence suggests that systemic elevation 
of A-SAAs might have an impact on the accumulation of senescent 
cells and the activation of their proinflammatory program at the 
organismal level. We found activation of TLR2 expression in parallel 
to A-SAAs in models of OIS in mice, in inflammation-induced 
senescence, in aging, and in different in vitro systems of senescence. 
Also, we have shown that TLR2 controls the activation of the SASP 
and OIS in vivo. Moreover, we have observed a dose-dependent 
effect for TLR2 in A-SAA sensing and a role for TLR2 in SASP activa-
tion during paracrine senescence. Together, these data suggest that 
systemic A-SAA elevation during acute inflammation could affect 
cells expressing TLR2, thereby promoting aging and other patho-
logical roles of senescence. Further investigation may reveal addition-
al physiological circumstances under which senescence is induced 
or reinforced by the interaction of TLR2 with A-SAAs or indeed 
with other endogenous DAMPs or exogenous PAMPs from the 
microbiome. These circumstances could have implications for 
organismal well-being, in particular, the development of aging and 
cancer.
Last, in recent years, several strategies have been implemented to 
eliminate senescent cells or to modulate the activation of the SASP 
in anti-aging and cancer therapies (senotherapies) (47–49). For 
example, genetic targeting for the elimination of senescent cells can 
delay organismal aging and aging-associated disorders (50, 51). 
Furthermore, the pharmacological suppression of the SASP has 
been shown to improve homoeostasis in tissue damage and aging 
(49). However, most of these manipulations are directed to essential 
homeostatic regulators such as mTOR or crucial proinflammatory 
mediators such as IL-1 signaling. Here, we propose the alternative 
of manipulating A-SAA–TLR2 as a new rationale for senotherapies 
aiming to manipulate nonessential and senescence-specific signaling 
pathways.
MATERIALS AND METHODS
Cell culture
Human embryonic kidney (HEK) 293T and IMR90 female human 
fetal lung fibroblast cells were obtained from American Type Culture 
Collection. All cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) (Thermo Fisher Scientific) supplemented with 
10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and 1% 
antibiotic-antimycotic solution (Thermo Fisher Scientific). IMR90 
cells were kept at 5% CO2 and ambient O2 at 37°C. All cell lines 
were regularly tested for mycoplasma contamination using the 
MycoAlert Mycoplasma Detection Kit (Lonza). Cell counting and 
viability were performed using the Muse Count and Viability Assay 
Kit in a Muse Cell Analyzer (Merck Millipore).
Experiments with mice
All work was compiled with the U.K. Home Office guiding principles 
for the care and use of laboratory animals. Mice carrying a condi-
tional Pdx1-Cre KrasG12D/+ allele were used and have been described 
previously (26). Aging experiments were carried out on male WT 
C57BL/6 mice or male nfkb1−/− mice on a pure C57BL/6 background 
at 6.5, 9.5, and 24 months of age. For hydrodynamic tail vein injection 
experiments, tlr2−/− mice on a C57BL/6 background were purchased 
from the Jackson Laboratory (JAX). Male and female tlr2−/− mice 
and WT siblings, aged between 8 to 12 weeks, were included in the 
study. Plasmids for hydrodynamic injection were prepared using the 
Qiagen Plasmid Maxi Kit (Qiagen, Germany), as per the manufacturer’s 
instructions. Animals received 6 g of a sleeping beauty transposase– 
encoding plasmid (CMV-SB 13 transposase), and 20 g of NRasG12V/
green fluorescent protein (GFP) encoding plasmid (pT3-NRasG12V-
IRES-GFP) was diluted in physiological saline to 10% of the animal’s 
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body weight (approximately 2 ml) and delivered via the lateral tail 
vein within 10 s. Plasmid encoding an NRasG12V effector loop mutant 
(pT3-NRasG12V/D38A-IRES-GFP), incapable of downstream NRas 
signaling, was used as a control. Mice were culled after 6 days, and 
liver tissue was harvested.
Chemical compounds and neutralizing antibodies
OIS was induced by treating IMR90 ER:RAS cells with 100 nM 
4OHT (Sigma-Aldrich). IMR90 ER:STOP was used as a negative 
control. To induce senescence, IMR90 cells were treated with 100 M 
etoposide for 48 hours, followed by 5 days in normal culture media, or 
with 10 M palbociclib or 10 M Nutlin 3a for 7 days. TLR2 was 
blocked by incubating cells with anti-TLR2 (10 g/ml) (MAB2616, 
R&D system) or immunoglobulin G2B isotype control. Chemical in-
hibitors used were 10 M BAY-117082 (Calbiochem), 10 M SB202190 
(Calbiochem), and OxPAPC (100 g/ml) (Invivogen). TLR2 in IMR90 cells 
was primed with recombinant human Apo-SAA (10 g/ml; PeproTech, 
catalog no. 300-30) or Pam2SK4 (1 g/ml; Tocris, catalog no. 4637).
Conditioned medium for paracrine senescence transmission
For the production of conditional medium used in paracrine senes-
cence, IMR90 ER:STOP or ER:RAS cells were cultured with 100 nM 
4OHT in DMEM supplemented with 10% FBS for 4 days, followed 
by DMEM supplemented with 1% FBS and 4OHT for an addi-
tional 4 days. The resulting conditioned medium was filtered with 
0.2-m syringe filters (Millipore) and reconstituted with a solution of 
DMEM supplemented with 40% FBS at a ratio of 3:1.
Construction of plasmids
TLR2 complementary DNA (cDNA) was amplified from the pcDNA3- 
TLR2-YFP plasmid (Addgene, 13016) using primers flanked with 
Xho I sites. Amplified genes were cloned into the MSCV-puro vector. 
pLN-ER:RAS, LSXN-ER:Stop, MSCV-RasG12V, CMV-VSVG, and 
pNGVL-Gag-Pol vectors were described elsewhere (15).
Retroviral production and infection
For retroviral production, retroviral vectors were cotransfected 
with VSV-G envelope plasmid and Gag-Pol helper vector using 
polyethylenimine linear (molecular weight, 25.000; Polysciences) 
into HEK293T cells. Viral supernatant was collected from the 
HEK293T cells 2 days after transfection and passed through a 0.45-m 
syringe filter (Merck Millipore) to eliminate cells. The viral super-
natant was supplemented with hexadimethrine bromide (4 g/ml; 
polybrene) (Sigma-Aldrich) and used to incubate IMR90 cells, with 
subsequent viral supernatant collection and treatment of IMR90 
cells every 3 hours. After three rounds of infection, the medium 
was changed to fresh DMEM with 10% FBS, and cells were 
allowed to grow for 2 to 3 days before selection with puromycin 
(1 g/ml) (Invivogen) for another 7 days before seeding for 
indicated experiments.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were dewaxed, rehydrated 
through graded ethanol solutions (100, 90, and 70%), and washed in 
distilled H2O. Endogenous peroxidase activity was blocked by 
immersing sections H2O2 (H1009, Sigma). To retrieve antigens, 
sections were boiled in 0.01 M citrate (pH 6.0), except for Tlr2 
staining where antigens were retrieved using proteinase K (20 g/ml). 
Sections were incubated with the primary antibody overnight at 4°C 
(antibody information is provided in table S3). For the Pdx1-Cre 
KrasG12D/+ mice experiment, the EnVision+ Dual Link System- 
HRP (DAB+) Kit (K4065, Dako) was used for Ki67 staining. The 
total number of Ki67-positive cells per PanIN and the total cells per 
PanIN were counted, and thus, the percentage of Ki67-positive cells 
per PanIN was calculated. The mean score for each mouse was 
calculated, and these scores were plotted on a box plot. Consecutive 
sections were stained with antibodies against Tlr2 and Saa1. For the 
nfkb−/− mice experiment, biotinylated secondary antibody was added 
and detected using the rabbit peroxidase ABC Kit (PK-4001, Vector 
Laboratories), according to the manufacturer’s instructions. Substrate 
was developed using the NovaRED Kit (SK-4800, Vector Laboratories). 
Staining was analyzed with a Nikon Eclipse E800 microscope, and 
images were captured with a Leica DFC420 camera using the LAS 
software (Leica). Ten to 15 random images were captured per 
section, and the percentage of positively stained cells determined 
from total number of cells before an average per mouse was calculated. 
For the hydrodynamic tail vein injection experiment, biotinylated 
secondary antibodies were added and detected using the R.T.U 
Vectastain Kit (PK-7100, Vector). Substrate was developed using 
the DAB substrate Kit (ab64238, Abcam). Staining was analyzed 
with a Hamamatsu NanoZoomer XR microscope, and images were 
captured using the NDP scan v.3.1 software (Hamamatsu).
Whole-mount SA--Gal staining
Snap-frozen liver samples were thawed before fixing in 2% 
formaldehyde/0.2% glutaraldehyde solution for 30 min at room 
temperature. Samples were subsequently washed with phosphate- 
buffered saline (PBS) and incubated at 37°C overnight in the dark 
in -Gal staining solution [5 mM K3FE (CN)6 and 5 mM K4Fe 
(CN) 6*3H2O in PBS, X-Gal solution (1 mg/ml), 150 mM NaCl, and 
2 mM MgCl2 at pH 6 in citric acid/phosphate buffer]. Samples were 
then washed, dehydrated, and imaged.
Biotin-SBB detection in paraffin-embedded sections
For Biotin-SBB IHC, paraffin-embedded sections were dewaxed, 
rehydrated, and blocked as per other IHC samples. Samples were 
immersed in additional graded ethanol washes before incubation with 
a Biotin-SBB analog (SenTraGor), which selectively binds to 
lipofuscin, for 8 min at room temperature. Samples were washed 
and then incubated with primary antibiotin antibody (see table S3) 
overnight at 4°C. The samples were then incubated with a horseradish 
peroxidase–conjugated secondary antibody for 1 hour at room tem-
perature, and then, substrate was developed using the DAB substrate 
Kit (ab64238, Abcam). Staining was analyzed with a Hamamatsu 
NanoZoomer XR microscope, and images were captured using the 
NDP scan v 3.1 software (Hamamatsu). The antibodies used are in 
table S3.
Herrings-testes DNA transfection
MR90 cells were seeded into six-well tissue culture plates, incubated 
overnight, and transfected with 2500 ng of herrings-testes DNA 
using Lipofectamine 2000, following the manufacturer’s protocol. 
Samples collected for analysis 24 hours after transfection.
siRNA transfection
Reverse siRNA transfection was carried out using 30 nM siRNA 
(Dharmacon, GE Healthcare). siRNA sequences are provided in 
table S2. DharmaFECT 1 (Dharmacon, GE Healthcare) transfection 
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reagent was diluted in DMEM and added to the siRNA-containing 
wells. This complex was allowed to form while cells were trypsinized 
and prepared for plating. IMR90 ER:RAS or ER:STOP cells (2000 cells 
per well in a 96-well plate; 66,000 cells per well in a six-well plate) 
were plated into the siRNA-containing wells with 100 nM 4OHT 
for the activation of ER:RAS. Because of the transient nature of siRNA 
to maintain the knockdown for up to 8 days, the cells were forward- 
transfected with medium containing the same proportions of siRNA, 
transfection reagent, and 4OHT on days 3 and 5. A list of the siRNA 
reagents is provided in table S2.
Total RNA preparation and quantitative reverse 
transcription polymerase chain reaction (qRT-PCR)
RNA was extracted from IMR90 cells using the RNeasy Plus 
Kit (Qiagen), following the manufacturer’s instructions. For mRNA 
expression in murine livers, snap-frozen specimens were homoge-
nized with trizole, and RNA was extracted using the Qiagen 
RNeasy plus mini kit (Qiagen, Germany), according to the manu-
facturer’s instructions. cDNA was synthesized using qScript cDNA 
SuperMix (Quanta Biosciences), following the manufacturer’s 
instructions, from 1 g of RNA in a 40-l reaction. qRT-PCR 
was performed using 1 l of cDNA as a template per reaction 
well and SYBR Select Master Mix (Life Technologies) using 200 nM 
of forward and reverse primers in 20 l. Samples were run in 
triplicate on a StepOnePlus Cycler (Thermo Fisher Scientific).
For the nfkb−/− aging experiment, RNA was extracted from 
solubilized lung tissue using the RNeasy Mini Kit (74106, Qiagen), 
according to the manufacturer’s instructions. cDNA was generated 
using the Omniscript RT Kit (205110, Qiagen) as per the user manual. 
qRT-PCR was performed using 4 l of cDNA as a template per 
reaction well using a Power SYBR Green (4367659, Invitrogen) 
PCR Master Mix and 100 nM of forward and reverse primers to 
form a final reaction volume of 10 l. Samples were run in triplicate in 
a C1000TM Thermal Cycler, CFX96TM Real-Time System (Bio-Rad), 
and Bio-Rad CXF manager software.
mRNA expression analysis was carried out using the change in 
Ct method and normalized to levels of the housekeeping gene actin or 
ribosomal protein 18S (nfkb−/− experiment only) to obtain relative 
mRNA expression. All primers used are listed in the table S1.
Immunofluorescence and high-content microscopy
All immunofluorescence staining and imaging was performed on 
the ImageXpress high-content analysis microscope (Molecular 
Devices), as previously described (52). All steps were carried out 
at room temperature. Following the indicated treatment, cells were 
fixed with 4% paraformaldehyde for 1 hour and permeabilized with 
0.2% Triton X-100 for 10 min. After three washes with PBS, the cells 
were blocked with 0.2% fish-skin gelatin/bovine serum albumin 
(BSA)/PBS for 1 hour. Primary antibodies were diluted in blocking 
solution as indicated and incubated for 30 min, followed by three 
washes in PBS. Appropriately conjugated Alexa Fluor secondary 
antibodies were diluted 1:1000 in blocking solution and incubated 
on the cells for 40 min, followed by an additional three washes 
in PBS. Last, 4′,6-diamidino-2-phenylindole (1 g/ml) was added 
to the cells for 20 min, after which the plates underwent a final 
round of washes before imaging on the ImageXpress microscope. 
Quantification of immunofluorescence images was conducted 
using the MetaXpress software (Molecular Devices), as previously 
described (52).
Western blot analysis
Whole-cell lysates were prepared by lysing the cells with an appro-
priate volume of radioimmunoprecipitation assay buffer [10 mM 
tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 
1% Triton X-100, 1 mM -mercaptoethanol, 0.5% sodium deoxy-
cholate, 10% glycerol, phosphatase inhibitor cocktail III, protease 
inhibitor cocktail V, and EDTA free]. Lysates were incubated on ice 
for 15 min before centrifuging at 14,000 rpm for 20 min to clear 
lysates. Supernatants were collected into a clean tube and quantified 
using the Bradford assay. Samples were prepared for loading by 
mixing with Laemmli sample buffer and boiled at 95°C for 5 min. 
Protein samples were resolved by polyacrylamide gel electrophoresis 
and transferred onto nitrocellulose membrane using the iBlot Dry 
Blotting System (Thermo Fisher Scientific). Membranes were blocked 
for 1 hour in 5% milk/tris-buffered saline–1% Tween (TBST). Indi-
cated primary antibodies were diluted in 5% milk/TBST or 5% BSA/
TBST and incubated at 4°C with gentle agitation overnight. Blots 
were washed for a minimum of three times in TBST for more than 
30 min. Secondary antibodies were prepared in 5% milk/TBST, and 
membranes were incubated at room temperature for 1 hour. Blots 
were washed as before, and then, enhanced chemical luminescence 
(Amersham) detection reagent was applied for detection. Antibody 
information is provided in table S3.
Cell proliferation assays
The 5-bromo-2′-deoxyuridine (BrdU) incorporation assay was used 
to measure the number of cells actively replicating DNA. Cells were 
treated as indicated in 96-well plates and incubated with 10 M BrdU 
(Sigma) for 16 to 18 hours before fixation and immunostained as 
described using anti-BrdU antibody with deoxyribonuclease (0.5 U/l) 
(Sigma) in 1 mM MgCl containing PBS.
To visualize and quantify long-term growth, cells were plated at 
low density (50,000 cells/10-cm plate) and maintained for 10 to 
15 days. The cells were fixed using 1% glutaraldehyde (Sigma) for 
1 hour and dried overnight before staining with 0.15% crystal violet 
solution for 2 hours. The plates were then washed, dried, and 
scanned for documentation. For quantification, crystal violet was 
extracted from stained plates with 1% acetic acid and quantified by 
absorbance read at 595 nm.
SA--Gal assay
SA--Gal staining solution was prepared using 20× KC [100 mM 
K3FE (CN)6 and 100 mM K4Fe (CN) 6*3H2O in PBS], 20× X-Gal 
solution (Thermo Fisher Scientific) diluted to 1× in PBS/1 mM 
MgCl2 at pH 5.5 to 6. The cells were treated as indicated and fixed 
in 0.5% glutaraldehyde (Sigma) for 10 min at room temperature. 
Cells were washed twice in PBS/1 mM MgCl2 (pH 5.5 to 6) before 
incubation in 2 ml of staining solution for 24 hours at 37°C.
AmpliSeq transcriptome profiling
RNA samples were assessed for quality on the Agilent Bioanalyzer 
with the RNA Nano Chip, providing an RNA Integrity Number. 
Samples were quantified using the Qubit 2.0 fluorometer and the 
Qubit RNA Broad Range assay. Ten nanograms of RNA was reverse- 
transcribed to make cDNA, and then, target genes were amplified for 
12 cycles of PCR using the Ion AmpliSeq Human Gene Expression 
Core Panel. This panel contains 20,802 amplicons (41,604 primers) 
of approximately 150 bases in length in a single pool. Ion Torrent 
sequencing adapters and barcodes were ligated to the amplicons, 
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and adapter-ligated libraries were purified using AMPure XP beads. 
Libraries were quantified by qPCR and diluted to 100 pM. Templates 
were prepared using the Ion PI Hi-Q OT2 200 Kit and sequenced 
using the Ion PI Hi-Q Sequencing 200 Kit. The Ion Proton platform 
was used to analyze the data. Analysis of gene expression was 
performed using the software package Babelomics 5.0 (53, 54). 
Statistical analysis of significance was performed using Benjamini and 
Hochberg false discovery rate multiple test. GSEA was performed 
using GSEA 3.0 software from the Broad Institute (www.gsea-
msigdb.org) (55). Gene ontology analysis was performed using DAVID 
functional annotation web resource (https://david-d.ncifcrf.gov).
Determination of IL-1 in conditioned medium
Supernatant of medium from siRNA-treated cells was collected for 
the analysis of IL-1 content. The medium was combined with 6× 
Laemmli sample buffer, and IL-1 expression was determined by 
immunoblotting, as described. Conditional medium samples were also 
analyzed for IL-1 expression by enzyme-linked immunosorbent 
assay (ELISA) using the Human IL-1 ELISA Ready-Set-Go! Kit 
(Affymetrix eBioscience), following the manufacturer’s instructions.
Quantification and statistical analysis
IHC images were quantified using ImageJ analysis software, and 
graphs and statistical analysis were carried out using GraphPad 
Prism version 7.0 (GraphPad Software, San Diego, CA).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/6/eaaw0254/DC1
Fig. S1. TLR2 expression is induced during OIS in vitro.
Fig. S2. TLR2 expression is induced during OIS in vivo.
Fig. S3. TLR2 and TLR10 regulate the SASP in OIS.
Fig. S4. TLR2 reinforces the cell cycle arrest in OIS.
Fig. S5. TLR2 and TLR10 regulate the activation of genes of the acute-phase response during OIS.
Fig. S6. A-SAA signaling through TLR2 controls the SASP.
Fig. S7. tlr2 is necessary for OIS activation in vivo.
Table S1. Primers used for qRT-PCR in this study.
Table S2. siRNA sequences used in this study.
Table S3. Antibodies used in this study.
Data file S1. Transcriptome analysis of the effect of TLR2 and TLR10 siRNAs in OIS.
Data file S2. Genes coregulated by TLR2 and TLR10 in OIS.
Data file S3. Genes regulated only by TLR10 in OIS.
REFERENCES AND NOTES
 1. T. Kuilman, C. Michaloglou, W. J. Mooi, D. S. Peeper, The essence of senescence.  
Genes Dev. 24, 2463–2479 (2010).
 2. M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach, S. W. Lowe, Oncogenic ras provokes 
premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 
593–602 (1997).
 3. M. Braig, S. Lee, C. Loddenkemper, C. Rudolph, A. H. F. M. Peters, B. Schlegelberger, 
H. Stein, B. Dörken, T. Jenuwein, C. A. Schmitt, Oncogene-induced senescence as an 
initial barrier in lymphoma development. Nature 436, 660–665 (2005).
 4. Z. Chen, L. C. Trotman, D. Shaffer, H.-K. Lin, Z. A. Dotan, M. Niki, J. A. Koutcher, H. I. Scher, 
T. Ludwig, W. Gerald, C. Cordon-Cardo, P. P. Pandolfi, Crucial role of p53-dependent cellular 
senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
 5. M. Collado, J. Gil, A. Efeyan, C. Guerra, A. J. Schuhmacher, M. Barradas, A. Benguría, 
A. Zaballos, J. M. Flores, M. Barbacid, D. Beach, M. Serrano, Tumour biology: Senescence 
in premalignant tumours. Nature 436, 642 (2005).
 6. M. Collado, M. Serrano, Senescence in tumours: Evidence from mice and humans.  
Nat. Rev. Cancer 10, 51–57 (2010).
 7. C. Michaloglou, L. C. W. Vredeveld, M. S. Soengas, C. Denoyelle, T. Kuilman, 
C. M. A. M. van der Horst, D. M. Majoor, J. W. Shay, W. J. Mooi, D. S. Peeper, BRAFE600-
associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005).
 8. J. C. Acosta, A. O’Loghlen, A. Banito, M. V. Guijarro, A. Augert, S. Raguz, M. Fumagalli, 
M. Da Costa, C. Brown, N. Popov, Y. Takatsu, J. Melamed, F. d'Adda di Fagagna, 
D. Bernard, E. Hernando, J. Gil, Chemokine signaling via the CXCR2 receptor reinforces 
senescence. Cell 133, 1006–1018 (2008).
 9. J.-P. Coppé, C. K. Patil, F. Rodier, Y. Sun, D. P. Muñoz, J. Goldstein, P. S. Nelson, 
P.-Y. Desprez, J. Campisi, Senescence-associated secretory phenotypes reveal 
cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.  
PLOS Biol. 6, 2853–2868 (2008).
 10. T. Kuilman, C. Michaloglou, L. C. W. Vredeveld, S. Douma, R. van Doorn, C. J. Desmet, 
L. A. Aarden, W. J. Mooi, D. S. Peeper, Oncogene-induced senescence relayed by an 
interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008).
 11. R. Salama, M. Sadaie, M. Hoare, M. Narita, Cellular senescence and its effector programs. 
Genes Dev. 28, 99–114 (2014).
 12. D. Muñoz-Espín, M. Serrano, Cellular senescence: From physiology to pathology.  
Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).
 13. L. Mosteiro, C. Pantoja, N. Alcazar, R. M. Marión, D. Chondronasiou, M. Rovira, 
P. J. Fernandez-Marcos, M. Muñoz-Martin, C. Blanco-Aparicio, J. Pastor, G. Gómez-López, 
A. De Martino, M. A. Blasco, M. Abad, M. Serrano, Tissue damage and senescence provide 
critical signals for cellular reprogramming in vivo. Science 354, aaf4445 (2016).
 14. B. Ritschka, M. Storer, A. Mas, F. Heinzmann, M. C. Ortells, J. P. Morton, O. J. Sansom, 
L. Zender, W. M. Keyes, The senescence-associated secretory phenotype induces cellular 
plasticity and tissue regeneration. Genes Dev. 31, 172–183 (2017).
 15. J. C. Acosta, A. Banito, T. Wuestefeld, A. Georgilis, P. Janich, J. P. Morton, D. Athineos, 
T.-W. Kang, F. Lasitschka, M. Andrulis, G. Pascual, K. J. Morris, S. Khan, H. Jin, 
G. Dharmalingam, A. P. Snijders, T. Carroll, D. Capper, C. Pritchard, G. J. Inman, T. Longerich, 
O. J. Sansom, S. A. Benitah, L. Zender, J. Gil, A complex secretory program orchestrated by 
the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–990 (2013).
 16. T.-W. Kang, T. Yevsa, N. Woller, L. Hoenicke, T. Wuestefeld, D. Dauch, A. Hohmeyer, 
M. Gereke, R. Rudalska, A. Potapova, M. Iken, M. Vucur, S. Weiss, M. Heikenwalder, S. Khan, 
J. Gil, D. Bruder, M. Manns, P. Schirmacher, F. Tacke, M. Ott, T. Luedde, T. Longerich, 
S. Kubicka, L. Zender, Senescence surveillance of pre-malignant hepatocytes limits liver 
cancer development. Nature 479, 547–551 (2011).
 17. V. Krizhanovsky, M. Yon, R. A. Dickins, S. Hearn, J. Simon, C. Miething, H. Yee, L. Zender, 
S. W. Lowe, Senescence of activated stellate cells limits liver fibrosis. Cell 134,  
657–667 (2008).
 18. W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, 
S. W. Lowe, Senescence and tumour clearance is triggered by p53 restoration in murine 
liver carcinomas. Nature 445, 656–660 (2007).
 19. M. Reimann, S. Lee, C. Loddenkemper, J. R. Dörr, V. Tabor, P. Aichele, H. Stein, B. Dörken, 
T. Jenuwein, C. A. Schmitt, Tumor stroma-derived TGF- limits Myc-driven 
lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 17, 262–272 (2010).
 20. H. Braumüller, T. Wieder, E. Brenner, S. Aßmann, M. Hahn, M. Alkhaled, K. Schilbach, 
F. Essmann, M. Kneilling, C. Griessinger, F. Ranta, S. Ullrich, R. Mocikat, K. Braungart, 
T. Mehra, B. Fehrenbacher, J. Berdel, H. Niessner, F. Meier, M. van den Broek, H.-U. Häring, 
R. Handgretinger, L. Quintanilla-Martinez, F. Fend, M. Pesic, J. Bauer, L. Zender, 
M. Schaller, K. Schulze-Osthoff, M. Röcken, T-helper-1-cell cytokines drive cancer into 
senescence. Nature 494, 361–365 (2013).
 21. D. Di Mitri, A. Toso, J. J. Chen, M. Sarti, S. Pinton, T. R. Jost, R. D’Antuono, E. Montani, 
R. Garcia-Escudero, I. Guccini, S. Da Silva-Alvarez, M. Collado, M. Eisenberger, Z. Zhang, 
C. Catapano, F. Grassi, A. Alimonti, Tumour-infiltrating Gr-1+ myeloid cells antagonize 
senescence in cancer. Nature 515, 134–137 (2014).
 22. Y. Chien, C. Scuoppo, X. Wang, X. Fang, B. Balgley, J. E. Bolden, P. Premsrirut, W. Luo, 
A. Chicas, C. S. Lee, S. C. Kogan, S. W. Lowe, Control of the senescence-associated 
secretory phenotype by NF-B promotes senescence and enhances chemosensitivity. 
Genes Dev. 25, 2125–2136 (2011).
 23. A. V. Orjalo, D. Bhaumik, B. K. Gengler, G. K. Scott, J. Campisi, Cell surface-bound IL-1 is 
an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network.  
Proc. Natl. Acad. Sci. U.S.A. 106, 17031–17036 (2009).
 24. M. Lamkanfi, V. M. Dixit, Mechanisms and functions of inflammasomes. Cell 157, 
1013–1022 (2014).
 25. O. Takeuchi, S. Akira, Pattern recognition receptors and inflammation. Cell 140,  
805–820 (2010).
 26. J. P. Morton, P. Timpson, S. A. Karim, R. A. Ridgway, D. Athineos, B. Doyle, N. B. Jamieson, 
K. A. Oien, A. M. Lowy, V. G. Brunton, M. C. Frame, T. R. J. Evans, O. J. Sansom, Mutant p53 
drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.  
Proc. Natl. Acad. Sci. U.S.A. 107, 246–251 (2010).
 27. D. Jurk, C. Wilson, J. F. Passos, F. Oakley, C. Correia-Melo, L. Greaves, G. Saretzki, C. Fox, 
C. Lawless, R. Anderson, G. Hewitt, S. L. F. Pender, N. Fullard, G. Nelson, J. Mann, 
B. van de Sluis, D. A. Mann, T. von Zglinicki, Chronic inflammation induces telomere 
dysfunction and accelerates ageing in mice. Nat. Commun. 5, 4172 (2014).
 28. S. Wang, M. Miura, Y.-k. Jung, H. Zhu, E. Li, J. Yuan, Murine caspase-11, an ICE-interacting 
protease, is essential for the activation of ICE. Cell 92, 501–509 (1998).
 29. S. Mariathasan, D. M. Monack, Inflammasome adaptors and sensors: Intracellular 
regulators of infection and inflammation. Nat. Rev. Immunol. 7, 31–40 (2007).
 o
n
 N
ovem
ber 14, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Hari et al., Sci. Adv. 2019; 5 : eaaw0254     5 June 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
14 of 14
 30. O. Takeuchi, T. Kawai, P. F. Mühlradt, M. Morr, J. D. Radolf, A. Zychlinsky, K. Takeda, 
S. Akira, Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13, 
933–940 (2001).
 31. O. Takeuchi, S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, S. Akira, 
Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial 
lipoproteins. J. Immunol. 169, 10–14 (2002).
 32. Y. Guan, D. R. E. Ranoa, S. Jiang, S. K. Mutha, X. Li, J. Baudry, R. I. Tapping, Human TLRs 10 
and 1 share common mechanisms of innate immune sensing but not signaling. 
J. Immunol. 184, 5094–5103 (2010).
 33. S. Akira, S. Uematsu, O. Takeuchi, Pathogen recognition and innate immunity. Cell 124, 
783–801 (2006).
 34. Y. Xu, N. Li, R. Xiang, P. Sun, Emerging roles of the p38 MAPK and PI3K/AKT/mTOR 
pathways in oncogene-induced senescence. Trends Biochem. Sci. 39, 268–276 (2014).
 35. C. Gabay, I. Kushner, Acute-phase proteins and other systemic responses to 
inflammation. N. Engl. J. Med. 340, 448–454 (1999).
 36. N. Cheng, R. He, J. Tian, P. P. Ye, R. D. Ye, Cutting edge: TLR2 is a functional receptor for 
acute-phase serum amyloid A. J. Immunol. 181, 22–26 (2008).
 37. N. Herranz, J. Gil, Mechanisms and functions of cellular senescence. J. Clin. Invest. 128, 
1238–1246 (2018).
 38. H. Jing, J. Kase, J. R. Dörr, M. Milanovic, D. Lenze, M. Grau, G. Beuster, S. Ji, M. Reimann, 
P. Lenz, M. Hummel, B. Dörken, G. Lenz, C. Scheidereit, C. A. Schmitt, S. Lee, Opposing 
roles of NF-B in anti-cancer treatment outcome unveiled by cross-species 
investigations. Genes Dev. 25, 2137–2146 (2011).
 39. J. S. Pawlikowski, T. McBryan, J. van Tuyn, M. E. Drotar, R. N. Hewitt, A. B. Maier, A. King, 
K. Blyth, H. Wu, P. D. Adams, Wnt signaling potentiates nevogenesis. Proc. Natl. Acad. 
Sci. U.S.A. 110, 16009–16014 (2013).
 40. J. C. Garbe, S. Bhattacharya, B. Merchant, E. Bassett, K. Swisshelm, H. S. Feiler, 
A. J. Wyrobek, M. R. Stampfer, Molecular distinctions between stasis and telomere 
attrition senescence barriers shown by long-term culture of normal human mammary 
epithelial cells. Cancer Res. 69, 7557–7568 (2009).
 41. E. Pazolli, X. Luo, S. Brehm, K. Carbery, J.-J. Chung, J. L. Prior, J. Doherty, S. Demehri, 
L. Salavaggione, D. Piwnica-Worms, S. A. Stewart, Senescent stromal-derived osteopontin 
promotes preneoplastic cell growth. Cancer Res. 69, 1230–1239 (2009).
 42. D. Muñoz-Espín, M. Cañamero, A. Maraver, G. Gómez-López, J. Contreras, S. Murillo-Cuesta, 
A. Rodríguez-Baeza, I. Varela-Nieto, J. Ruberte, M. Collado, M. Serrano, Programmed cell 
senescence during mammalian embryonic development. Cell 155, 1104–1118 (2013).
 43. Z. Dou, K. Ghosh, M. G. Vizioli, J. Zhu, P. Sen, K. J. Wangensteen, J. Simithy, Y. Lan, Y. Lin, 
Z. Zhou, B. C. Capell, C. Xu, M. Xu, J. E. Kieckhaefer, T. Jiang, M. Shoshkes-Carmel, 
K. M. A. A. Tanim, G. N. Barber, J. T. Seykora, S. E. Millar, K. H. Kaestner, B. A. Garcia, 
P. D. Adams, S. L. Berger, Cytoplasmic chromatin triggers inflammation in senescence 
and cancer. Nature 550, 402–406 (2017).
 44. J. Ling, Y. Kang, R. Zhao, Q. Xia, D.-F. Lee, Z. Chang, J. Li, B. Peng, J. B. Fleming, H. Wang, 
J. Liu, I. R. Lemischka, M.-C. Hung, P. J. Chiao, KrasG12D-induced IKK2//NF-B activation 
by IL-1 and p62 feedforward loops is required for development of pancreatic ductal 
adenocarcinoma. Cancer Cell 21, 105–120 (2012).
 45. N. Tasdemir, A. Banito, J.-S. Roe, D. Alonso-Curbelo, M. Camiolo, D. F. Tschaharganeh, 
C.-H. Huang, O. Aksoy, J. E. Bolden, C.-C. Chen, M. Fennell, V. Thapar, A. Chicas, C. R. Vakoc, 
S. W. Lowe, BRD4 connects enhancer remodeling to senescence immune surveillance. 
Cancer Discov. 6, 612–629 (2016).
 46. S. Glück, B. Guey, M. F. Gulen, K. Wolter, T.-W. Kang, N. A. Schmacke, A. Bridgeman, 
J. Rehwinkel, L. Zender, A. Ablasser, Innate immune sensing of cytosolic chromatin 
fragments through cGAS promotes senescence. Nat. Cell Biol. 19,  
1061–1070 (2017).
 47. D. McHugh, J. Gil, Senescence and aging: Causes, consequences, and therapeutic 
avenues. J. Cell Biol. 217, 65–77 (2018).
 48. J. C. Acosta, J. Gil, Senescence: A new weapon for cancer therapy. Trends Cell Biol. 22, 
211–219 (2012).
 49. B. G. Childs, M. Gluscevic, D. J. Baker, R.-M. Laberge, D. Marquess, J. Dananberg, 
J. M. van Deursen, Senescent cells: An emerging target for diseases of ageing.  
Nat. Rev. Drug Discov. 16, 718–735 (2017).
 50. D. J. Baker, B. G. Childs, M. Durik, M. E. Wijers, C. J. Sieben, J. Zhong, R. A. Saltness, 
K. B. Jeganathan, G. C. Verzosa, A. Pezeshki, K. Khazaie, J. D. Miller, J. M. van Deursen, Naturally 
occurring p16Ink4a-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016).
 51. D. J. Baker, T. Wijshake, T. Tchkonia, N. K. LeBrasseur, B. G. Childs, B. van de Sluis, 
J. L. Kirkland, J. M. van Deursen, Clearance of p16Ink4a-positive senescent cells delays 
ageing-associated disorders. Nature 479, 232–236 (2011).
 52. P. Hari, J. C. Acosta, Detecting the senescence-associated secretory phenotype (SASP) by 
high content microscopy analysis. Methods Mol. Biol. 1534, 99–109 (2017).
 53. F. Al-Shahrour, L. Arbiza, H. Dopazo, J. Huerta-Cepas, P. Mínguez, D. Montaner, J. Dopazo, From 
genes to functional classes in the study of biological systems. BMC Bioinformatics 8, 114 (2007).
 54. R. Alonso, F. Salavert, F. Garcia-Garcia, J. Carbonell-Caballero, M. Bleda, L. Garcia-Alonso, 
A. Sanchis-Juan, D. Perez-Gil, P. Marin-Garcia, R. Sanchez, C. Cubuk, M. R. Hidalgo, 
A. Amadoz, R. D. Hernansaiz-Ballesteros, A. Alemán, J. Tarraga, D. Montaner, I. Medina, 
J. Dopazo, Babelomics 5.0: Functional interpretation for new generations of genomic 
data. Nucleic Acids Res. 43, W117–W121 (2015).
 55. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, 
A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment 
analysis: A knowledge-based approach for interpreting genome-wide expression 
profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545–15550 (2005).
Acknowledgments: We especially thank M. Christophorou, A. von Kriegsheim,  
N. Gammoh, T. Chandra, C. Bishop, C. Wellbrock, N. Hastie, A. Jackson, M. Reijns, P. Adams, 
A. Banito, and all the members of J.C.A.’s laboratory for helpful criticism, discussion, and 
encouragement. We thank the CRUK Glasgow Centre and the BSU facilities and Histology 
Service at the CRUK Beatson Institute. We also thank S. W. Lowe for pT3-NRasG12V-IRES-GFP, 
pT3-NRasG12V/D38A-IRES-GFP, and CMV-SB13 plasmids. Funding: This work was supported by 
Cancer Research UK (C47559/A16243, Training and Career Development Board–Career 
Development Fellowship), University of Edinburgh (Chancellor’s Fellowship), and the Wellcome 
Trust-ISSF. P.H., I.F.-D., and N.T. were funded by the University of Edinburgh Chancellor’s 
Fellowship. J.F.P. and J.B. were funded by BBSRC (grant no. BB/K017314/1). F.R.M. is funded by a 
Wellcome Trust Clinical Research Fellowship through the Edinburgh Clinical Academic Track 
(ECAT) (203913/Z/16/Z). J.P.M. and C.J.R. are funded by CRUK (A20409 and A25142). Author 
contributions: Conceptualization: J.C.A.; formal analysis; P.H, F.R.M., N.T., J.B., J.F.P., J.P.M, and 
J.C.A; investigation: P.H., F.R.M., I.F.-D., N.T., A.Q., C.J.R., J.B., J.P.M., L.B., and J.C.A.; resources; 
J.P.M. L. B., M.M., and V.G.B.; data curation: J.C.A; writing (original draft): J.C.A.; writing (review 
and editing): A.J.F., F.R.M., and P.H.; visualization: P.H., I.F.-D., N.T., J.B., J.F.P., and J.C.A; 
supervision: J.C.A.; funding acquisition: J.C.A. Competing interest: The authors declare that 
they have no competing interest. Data and materials availability: All data needed to evaluate 
the conclusions in the paper are present in the paper and the Supplementary Materials. 
Additional data related to this paper may be requested from authors. AmpliSeq Transcriptomic 
RNA-seq data in this study are deposited at the Gene Expression Omnibus under the accession 
no. GSE127116. Further information and requests for resources and reagents should be 
directed to and will be fulfilled by the lead contact J.C.A. (juan-carlos.acosta@igmm.ed.ac.uk).
Submitted 11 November 2018
Accepted 26 April 2019
Published 5 June 2019
10.1126/sciadv.aaw0254
Citation: P. Hari, F. R. Millar, N. Tarrats, J. Birch, A. Quintanilla, C. J. Rink, I. Fernández-Duran, 
M. Muir, A. J. Finch, V. G. Brunton, J. F. Passos, J. P. Morton, L. Boulter, J. C. Acosta, The innate 
immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype. 
Sci. Adv. 5, eaaw0254 (2019).
 o
n
 N
ovem
ber 14, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
phenotype
The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory
Muir, Andrew J. Finch, Valerie G. Brunton, João F. Passos, Jennifer P. Morton, Luke Boulter and Juan Carlos Acosta
Priya Hari, Fraser R. Millar, Nuria Tarrats, Jodie Birch, Andrea Quintanilla, Curtis J. Rink, Irene Fernández-Duran, Morwenna
DOI: 10.1126/sciadv.aaw0254
 (6), eaaw0254.5Sci Adv 
ARTICLE TOOLS http://advances.sciencemag.org/content/5/6/eaaw0254
MATERIALS
SUPPLEMENTARY http://advances.sciencemag.org/content/suppl/2019/06/03/5.6.eaaw0254.DC1
REFERENCES
http://advances.sciencemag.org/content/5/6/eaaw0254#BIBL
This article cites 55 articles, 17 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
 is a registered trademark of AAAS.Science AdvancesYork Avenue NW, Washington, DC 20005. The title 
(ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 NewScience Advances 
BY).
Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC 
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of
 o
n
 N
ovem
ber 14, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
